Imunon’s (IMNN) Buy Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Imunon (NASDAQ:IMNN) in a research report report published on Thursday morning, Benzinga reports. HC Wainwright currently has a $14.00 price objective on the stock.

Imunon Price Performance

IMNN stock opened at $1.14 on Thursday. Imunon has a 12 month low of $0.48 and a 12 month high of $3.65. The firm’s 50-day moving average is $1.25 and its 200 day moving average is $1.17. The company has a market capitalization of $10.72 million, a PE ratio of -0.56 and a beta of 2.12.

Imunon Company Profile

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.